Disease · MONDO_0100342
malignant glioma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. malignant glioma. Diseases, record MONDO_0100342. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100342
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
glial cell tumour, glioma, malignant, high grade glioma, malignant glial neoplasm, malignant glial tumor, malignant glial tumour, malignant neuroglial neoplasm, malignant neuroglial tumor, malignant neuroglial tumour
- Open Targets
Drugs208
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Approval | PMDA | 81 | 80 | 80 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Approval | PMDA | 11 | 10 | 10 | Drugs and targets |
| AMINOLEVULINIC ACID HYDROCHLORIDE | CHEMBL1200582 | Small molecule | Approval | PMDA | 4 | 3 | 1 | Drugs and targets |
| FLUCICLOVINE F18 | CHEMBL254468 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 36 | 36 | 36 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
1 to 10 of 208
See all 208 drugsTargets245
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 10 | Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 9 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 9 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 8 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 8 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 7 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 7 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 7 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 7 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 245
See all 245 targetsTrials318
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00602667 | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Phase 2 | 293 | 2019-01-30 | Brain and Central Nervous System Tumors | CYCLOPHOSPHAMIDE, METHOTREXATE, TOPOTECAN, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Phase 2 | 206 | 2023-08-21 | Cancer | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02655601 | Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 | Phase 1/2 | 177 | 2025-06-08 | High Grade Glioma, Astrocytoma, Grade III, Glioblastoma | BMX-001, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Phase 2 | 166 | 2021-04-01 | Various Advanced Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00727506 | BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma | Phase 2 | 151 | 2014-01-24 | Glioma | AFATINIB, TEMOZOLOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01137604 | A Study in Subjects With Recurrent Malignant Glioma | Phase 2 | 151 | 2016-05-23 | Glioma | BEVACIZUMAB, LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | Phase 2 | 151 | 2023-05-19 | Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Iponeurocytoma | DABRAFENIB, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00892177 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | Phase 2 | 144 | 2017-06-27 | Glioblastoma Multiforme | BEVACIZUMAB, DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | Phase 1/2 | 136 | 2017-07-13 | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Recurrent Adult Brain Tumor | ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00200161 | Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma | Phase 2 | 127 | 2018-03-07 | Glioblastoma, Gliomas | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 318
See all 318 trialsComparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Ph 2 Radiation Therapy, TMZ and BMX-001 vs Arm B: Ph 2 Radiation Therapy and TMZ: Phase 2: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 17 of 80 | 13 of 80 | 160 | NCT02655601 | Trial comparisons |
| Arm A: Ph 2 Radiation Therapy, TMZ and BMX-001 vs Arm B: Ph 2 Radiation Therapy and TMZ: Phase 2: Protection of Bone Marrow Against Chemotherapy-Induced Thrombocytopenia | 1 of 78 | 2 of 71 | 149 | NCT02655601 | Trial comparisons |
| Phase 1 Dose Escalation vs Phase 2 Recurrent Malignant Gliomas and Nonprogressive Gbm: serious adverse events | 0 of 32 | 2 of 99 | 131 | NCT00045110 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response | 5 of 93 | 2 of 27 | 120 | NCT02986178 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev | 17 of 94 | 8 of 26 | 120 | NCT02986178 | Trial comparisons |
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: Number of Participants With Adverse Events | 44 of 44 | 43 of 43 | 87 | NCT00923117 | Trial comparisons |
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: serious adverse events | 16 of 44 | 13 of 43 | 87 | NCT00923117 | Trial comparisons |
| Metronomic Therapy Cohort vs Dose-Dense Therapy Cohort: deaths from any cause | 0 of 43 | 1 of 42 | 85 | NCT00200161 | Trial comparisons |
| Metronomic Therapy Cohort vs Dose-Dense Therapy Cohort: serious adverse events | 0 of 43 | 0 of 42 | 85 | NCT00200161 | Trial comparisons |
| Enzastaurin + Bevacizumab (NEIAED) vs Enzastaurin + Bevacizumab (EIAED): serious adverse events | 24 of 68 | 4 of 13 | 81 | NCT00586508 | Trial comparisons |
1 to 10 of 43
See all 43 comparisons in its trialsPapers from its trials145
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100342
GET https://conductscience.org/api/diseases/v1/MONDO_0100342/drugs?page=2